🎉 Breaking News from Trutino Biosciences! 🎉
🚀 FDA IND Approval Secured! 🚀

What happens when a small but mighty start-up dreams big? Magic. The Trutino Team is thrilled to announce our successful IND approval by the FDA. We’re not just popping champagne—though we might do that too—we’re gearing up to treat cancer patients in the clinic in just a few weeks!

A HUGE shoutout to Partner’s Investment for believing in a team that had never made its own drug before. Who knew a small start-up with audacious dreams could make waves? (Spoiler: we did.) 🌊💪

To our amazing friends and colleagues at Boehringer Ingelheim: you’ve been there since the world came to a standstill, proving that nothing—pandemic included—could stop innovation and friendship. Here’s to the start of something incredible as we champion our On Demand Cytokine Platform together.

Endless thanks to our advisors and collaborators for keeping us grounded with your wisdom and insights. And to our unsung heroes—the industry CDMO, CRO, and regulatory partners who must remain anonymous due to confidentiality—you’ve been our North Star in this journey.

🎊 This milestone is more than an approval—it’s a testament to the power of ambition, collaboration, and an unwavering commitment to making a difference in cancer care. Here’s to many more milestones ahead! Trutino Biosciences: Creating hope, one breakthrough at a time. 🌟